Generic Baraclude market seen to be overheated

Published: 2012-10-05 06:56:00

Updated: 2012-10-05 06:56:00

The domestic pharmaceutical industry is struggling with the fallout of the American pharmaceutical firm Bristol Myers Squibb (BMS)’s setback in the domestic anti-hepatitis B drug market.

Nearly 40 kinds of Baraclude generics will flood the market following the expiration of Baraclude’s re-exa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK